Coronavirus Infection Clinical Trial
— COVIDOROfficial title:
Epidemiological Study of the Covid-19 Presto Test Among Agents of the Local Authorities of CCTVL, Region Centre Val de Loire and Orleans Métropole. Correlation of IgM Level According to Contact With the Public
Verified date | October 2021 |
Source | Orléans Métropole Service de Médecine Préventive |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The "COVIDOR" epidemiological study. Our study would be the first at the community level in Orleans Métropole, aiming to determine the link between a positive IgM level on the serological test and a healthy carrier of covid-19 in agents in contact with the public. It would provide epidemiological surveillance of anti-covid-19 immunity in the community
Status | Completed |
Enrollment | 3228 |
Est. completion date | October 4, 2021 |
Est. primary completion date | July 13, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - All the agents of the 3 local authorities (Loire Valley Region, CCTVL and Orléans Métropole) being voluntary to be tested for the COVID-PRESTO® test COVID-19 IgG / IgM rapid test (whole blood / serum / plasma) - Cassette - Volunteer to get tested Exclusion Criteria: - Opposition to the participation of the study - Covid-19 disease |
Country | Name | City | State |
---|---|---|---|
France | Unité de Recherche PARADICT-O - Orléans | Orléans | |
France | Unité de Recherche PARADICT-O - Service de Médecine - Orléans Métropole | Orléans |
Lead Sponsor | Collaborator |
---|---|
Raphael Serreau | Assistance Publique - Hôpitaux de Paris, François Rabelais University, University Hospital, Paris |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Study the prevalence of Covid-19 infection, coronavirus (SARS coronavirus-2) in territorial agents in the 3 structures : CCTVL, Loire Valley Region Centre, Orleans Metropolitan city | Covid-19 attack rate by measuring the frequency of anti-covid-19 IgM in each of the territorial structures | 15 minutes | |
Secondary | Determine if there is a relationship between the profession carried out by the agents of the territorial community of Orleans metropolitan city, the Loire Valley Region, the CCTVL and contamination by covid-19 | Search for a correlation of covid-19 immunity based on the officer's position, if he is in contact with the public. | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04369456 -
Blood Biomarkers as Predictors of COVID-19 Disease Progression in Recently Infected Kidney Transplant Patients
|
N/A | |
Completed |
NCT04527471 -
Pilot Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19
|
Phase 2 | |
Recruiting |
NCT04410510 -
P2Et Extract in the Symptomatic Treatment of Subjects With COVID-19
|
Phase 2/Phase 3 | |
Withdrawn |
NCT04383899 -
Role of Ibuprofen and Other Medicines on Severity of Coronavirus Disease 2019
|
||
Completed |
NCT04542915 -
COVID-19-Related Health and Practices Among Dental Hygienists
|
||
Not yet recruiting |
NCT04400019 -
Prevention of COVID19 Infection in Nursing Homes by Chemoprophylaxis With Hydroxychloroquine (PREVICHARM)
|
Phase 2/Phase 3 | |
Suspended |
NCT04385771 -
Cytokine Adsorption in Patients With Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation
|
N/A | |
Completed |
NCT04532632 -
Taste and Smell Impairment in Critically Ill COVID-19 Patients
|
||
Terminated |
NCT04954014 -
Pilot Study of Single Dose Bevacizumab as Treatment for Acute Respiratory Distress Syndrome (ARDS) in COVID-19 Patients
|
Phase 2 | |
Terminated |
NCT04530448 -
Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization
|
Phase 4 | |
Completed |
NCT04413435 -
Clinical Characteristics of Critically Ill Patients With COVID-19
|
||
Terminated |
NCT05593770 -
International Sites: Novel Experimental COVID-19 Therapies Affecting Host Response
|
Phase 2/Phase 3 | |
Completed |
NCT04510493 -
Canakinumab in Patients With COVID-19 and Type 2 Diabetes
|
Phase 3 | |
Active, not recruiting |
NCT04587219 -
The Study of "Gam-COVID-Vac" Vaccine Against COVID-19 With the Participation of Volunteers of 60 y.o and Older
|
Phase 2 | |
Withdrawn |
NCT05430958 -
Safety, Tolerability and Immunogenicity of INO-4800 for COVID19 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04596579 -
SARS-CoV-2 (COVID-19) Immune Surveillance Among a Population Based Sample of Adults in Florida
|
||
Completed |
NCT04405934 -
COG-UK Project Hospital-Onset COVID-19 Infections Study
|
N/A | |
Enrolling by invitation |
NCT04484025 -
SPI-1005 Treatment in Moderate COVID-19 Patients
|
Phase 2 | |
Terminated |
NCT04442230 -
NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19)
|
Phase 2 | |
Terminated |
NCT04642638 -
Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure
|
Phase 2/Phase 3 |